Published • loading... • Updated
Sandoz introduces Owozy semaglutide in Brazil following ANVISA approval for type-2 diabetes
Summary by EuropaWire.eu
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Sandoz introduces Owozy semaglutide in Brazil following ANVISA approval for type-2 diabetes
Developed by Adalvo and marketed locally by Biolab & Co the once-weekly injectable treatment advances Sandoz's international GLP-1 strategy IN BRIEFKEY TAKEAWAYSFAQs Sandoz has launched Owozy (semaglutide solution for injection) in Brazil, marking its first commercial semaglutide introduction in one … Read the full press release →
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
